Boston Scientific Vessix Renal Denervation System Data Show Significant and Sustained Reduction in Blood Pressure,
Patients treated with the Boston Scientific (NYSE: BSX) Vessix™ Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to new data presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco. An interim analysis of 139 patients enrolled in the REDUCE-HTN post market study affirms the device safety profile and effective treatment for resistant hypertension.
"In the REDUCE-HTN study, 85 percent of patients treated with the Vessix System experienced a clinically-meaningful decrease in blood pressure," said Professor Horst Sievert, M.D., Ph.D., director of the CardioVascular Center Frankfurt, Sankt Katharinen Hospital in Frankfurt, Germany, and principal investigator in the REDUCE-HTN clinical program. "In my opinion, the large patient cohort and rigorous analysis of the study suggest that renal denervation using bipolar technology will be an important part of the treatment algorithm for a wide variety of patients with resistant hypertension."
Renal denervation with the Vessix System is a minimally-invasive procedure in which a balloon catheter is fed through the arterial vascular system and positioned in the renal arteries, the major blood vessels that lead to the kidneys. The physician then delivers